问题 › AI 正在改变我们的行业 › 医疗服务提供商
问题不在于 AI 能做什么，而在于你从基于价值合同覆盖的 38,000 例归因生命中获得的收入，哪一部分会变得更容易被其他人管理。 医疗服务提供商面临的具体困境是：已在 38,000 例生命上承担了下行风险，却缺乏按单次事件成本定价所需的数据。在定价完成前，单次事件成本会持续变动且无人能归因，按收入线划分风险的讨论仍停留在意见层面。
问题不在于 AI 能做什么，而在于你从基于价值合同覆盖的 38,000 例归因生命中获得的收入，哪一部分会变得更容易被其他人管理。 医疗服务提供商面临的具体困境是：已在 38,000 例生命上承担了下行风险，却缺乏按单次事件成本定价所需的数据。在定价完成前，单次事件成本会持续变动且无人能归因，按收入线划分风险的讨论仍停留在意见层面。
多数 AI 战略讨论从能力出发，最终无果，因为能力不是决定结果的变量。变量是：那些与合同下单次事件成本相关的具体工作，是否会让竞争对手或支付方自己处理起来大幅降低成本。
这可以逐行回答。对归因生命产生的每一条收入线：单次事件成本中被自动化的工作占比多少，贡献额中有多少由支付方组合或患者面板规模等其他因素保护，以及一个可信竞争对手在相同合同上达到同等水平需要多长时间。
通常发现的问题是：暴露的收入线往往是盈利的，因为高毛利工作通常是与管理单次事件相关的信息工作。应对方式很少是更快采用工具，而是把收费内容转向价值导向合同下自动化使其更有价值而非更低价值的领域。
这三者同时出现才是标志。单独一个通常指向其他问题。
✓ 压力表现为单次事件成本超出基于价值合同允许的范围。
✓ 支付方或内部审查开始询问，为什么一次事件仍需要当前水平的提供者时间。
✓ 同类基于价值合同下的新进入者，以更低的单次事件成本管理归因生命。
通常会让情况更糟的做法。 直接采用工具却不改变收费内容，结果同时压低单次事件成本和合同费率，贡献额维持原状。
It is for you if you run or finance a healthcare provider and the pressure is showing up as price, not as lost deals. It is the situation where the numbers are available but nobody has put them in an order that produces a decision.
It is not for you if Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Below is an excerpt from a real run of this analysis on 一家医疗服务提供商. It is a sample profile rather than a customer, and it is engine output translated from English — this is the format you get, on your own numbers.
The subject is Cedar Ridge Health Partners, a sample company profile used for testing rather than a customer — 38,000 attributed lives under value-based contracts.
Excerpt from a real Percision run · Customer Value Architecture · sample company profile
The move. Convert existing downside-risk scale into CMS-mandated quality infrastructure that locks in 48+ month structural durability.
The leak it closes. Binary default risk on $6.8M revenue eliminated through cost-per-episode analytics
The assumption it rests on. CMS continues ACO REACH program through 2030 — the engine put the probability at 0.85.
| Investment required | $225-325K total over 36 months ($75K regulatory consultant + $150-250K analytics tooling) |
| Expected return | 69.8× on $325K investment if ACO REACH approved — derived from $22.7M NPV upside / $325K investment |
| Revenue, year 1 | $0 incremental (application phase) |
| Revenue, year 2 | $1.0M incremental (0.5 point margin lift on $196M) |
| Revenue, year 3 | $2.0M incremental (1.0 point margin lift on $196M) |
| Exit criteria | Abandon if CMS terminates ACO REACH program OR physician ownership falls below 55% OR application rejected after two submissions |
This is one move out of a full analysis. Read a complete report — every page, no email required.
This question routes to AI Horizon, one of 29 engagements the platform runs. For 医疗服务提供商 it works through cost per episode, payer mix, panel size and contribution per provider, then produces the sequence rather than a list of options — which move first, what it funds, and the observation that would say the sequence is wrong.
You watch the analysis get built before paying anything. 在此阅读完整报告 if you would rather see the depth first.
通常先内部使用更合适，因为这能在对客户做出承诺前，先拿出自身经济数据的证据。除非竞争对手已重置客户预期，此时内部效率提升已来不及。
用价格判断，而非公告。当你所售产出的市场价格开始下降时，无论技术还能演示什么，颠覆已然到来。
规模较小的企业通常有更快调整收费内容的优势。关键动作是重新定位，这对你的成本低于需要保护庞大存量的大型企业。
Materially, yes. Downside risk has been accepted on 38,000 lives without the cost-per-episode data needed to price it — which changes both the diagnosis and the order of the fixes. The metrics that decide it here are cost per episode, payer mix, panel size, and an answer built on industry-general benchmarks will usually point at the wrong one first.
Less than most people expect. Your last twelve months of revenue and cost split the way you already split it, plus whatever you hold on cost per episode and payer mix. The analysis is explicit about what it is assuming where your data stops, which is more useful than waiting for numbers you may never have.
Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Describe the situation in your own words and we will tell you which analysis answers it — before you sign up for anything.
Describe my situation →Prefer to skip ahead? Go straight to the free diagnostic.
English · Español · Deutsch · Português · Français · Italiano · Nederlands · 日本語 · 한국어 · 中文 · Polski · Svenska · Türkçe · العربية · Tiếng Việt · ไทย · हिन्दी · עברית